iohexol has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 1 |
| Fisher, R; Gutzeit, A; Koh, DM; Larkin, J; Lote, H; Sohaib, A; Thian, Y | 1 |
2 other study(ies) available for iohexol and su 11248
| Article | Year |
|---|---|
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2014 |